Sucralfate
FDA Approved, EMA Approved
Contents
Description
Sucralfate is a mucosal protective agent that forms a protective barrier over ulcerated tissue. It has been used in the management of solitary rectal ulcer syndrome to promote healing and reduce symptoms. Sucralfate works by binding to proteins in damaged mucosa, creating a protective coating that shields the ulcer from acid, pepsin, and bile salts.
Indications & Therapeutic Use
Solitary rectal ulcer syndrome, peptic ulcer disease, gastroesophageal reflux disease
Global Availability (10 countries)
| Country | Access Route | Regulatory Pathway | Lead Time | Status |
|---|---|---|---|---|
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — |
Buy / Source Sucralfate — GNH India
54 matching products available through GNH India. Select a product to view details and request a quote on the GNH India website.
Andapsin
EU
Antepsin
EU
APO-SUCRALFATE - TAB 1G
1 GtabletCANADA
Keal
EU
Peptonorm
EU
Sparacid ds Suspension 100 ml
100 mg/5mlsyrup
Sucrabest
EU
Sucrafil Suspension 200 ml
500mg/5mlsyrup
Products and ordering are fulfilled by GNH India. You will be redirected to www.gnhindia.com.
Available Through
This drug is available for procurement through the following fulfilment partner.
Fulfilment Partner
Sucralfate
| Generic Name | Sucralfate |
| Brands | 1 brand available |
| Active Ingredient | Sucralfate |
| Drug Class | Solitary rectal ulcer syndrome |
| Manufacturer | Various |
| Dosage Forms | Oral tablets 1g, oral suspension 1g/10mL, rectal suppositories |
| Medical Code | A02BX02 |
| Orphan Status | No |
| Cold Chain | Not Required |
| Lead Time | 3 days |
| Reg. Status | FDA Approved, EMA Approved |
| Countries | 10 countries |
Authority Signals
Last Verified3/21/2026
Data ConfidenceHigh (AI + Pharmacist)
Source Citations11 Validated Nodes